ArticleAnnals of the rheumatic diseases2019
Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?
Article in Annals of the rheumatic diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.Annals of the rheumatic diseases · 2021Guideline
- Rheumatic immune-related adverse effects of immune checkpoint treatment: a retrospective multicentre study.Scientific reports · 2026Observational
- Spectrum mining of immune checkpoint inhibitor-related cutaneous toxicities and analysis of associated factors based on FAERS.Frontiers in pharmacology · 2025Article
- Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica.Annals of the rheumatic diseases · 2022Article
- Palliative care physicians' recognition of patients after immune checkpoint inhibitors and immune-related adverse events.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Knowledge gap about immune checkpoint inhibitors among rheumatologists and medical students: a survey.Rheumatology international · 2021Observational
- Autoimmunity in 2019.Clinical reviews in allergy & immunology · 2020Review
- Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment.Rheumatology international · 2020Review
- Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach.Internal and emergency medicine · 2020Review
- Immune-related adverse events of checkpoint inhibitors.Nature reviews. Disease primers · 2020Review
- Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.Rheumatology (Oxford, England) · 2019Review
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30659050What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.